Hexarelin vs Sermorelin: Mechanism, Similarities, Differences, and Side Effects

Hexarelin and sermorelin are the two new synthetic peptides. They consist of small chains of amino acid molecules and have the potential to influence growth hormone patterns in research models. In preclinical investigations, Hexarelin and Sermorelin have demonstrated promising potential in relation to skeletal muscle protein synthesis, adipose tissue regulation, and cellular senescence pathways in research subjects. To explore them further, here is a detailed blog.

In this blog, we will discuss the nature of hexarelin and sermorelin, similarities, differences, side effects, and the best choice. Finish this read to get the complete picture! 

What is Hexarelin?

Buy Hexarelin Acetate

Hexarelin is a synthetic peptide consisting of 6 amino acid molecules. It is also known as a growth hormone secretagogue or growth hormone-releasing peptide. During clinical trials, it was studied to mimic the working patterns of naturally occurring hormones, such as ghrelin. Influencing the patterns related to ghrelin hormones may improve the secretion of growth hormones from the pituitary gland of research models. As growth hormone (GH) levels increase, it may influence physiological parameters associated with tissue development, energy substrate utilization, physical capacity, metabolic efficiency, appetite regulation, and overall metabolic function in research subjects.

What is Sermorelin?

Buy Sermorelin

Sermorelin is a synthetic peptide of 29 amino acid molecules. It belongs to the group of growth hormone-releasing peptides or growth hormone secretagogues. In preclinical trials, it has shown promising benefits by mimicking the effects of growth hormone-releasing peptide. One of its promising benefits was affecting the release patterns of growth hormones from the pituitary gland of research models in trials. In return, the growth hormones have influenced the physiological and molecular endpoints related to skeletal muscle development, lipid metabolism, age-associated biological processes, and metabolic regulation in research models.

Mechanism of Action

Here are the mechanisms of action of Hexarelin and Sermorelin peptides: 

Mechanism of Action of Hexarelin

During research studies on animals, Hexarelin has been shown to have the potential to bind to ghrelin receptors. The ghrelin receptors, in return, have improved the patterns linked with growth hormone secretion from the hypothalamus of the pituitary gland in research subjects. Consequently, the levels of growth hormones were improved in subjects during the research investigation. 

Mechanism of Action of Sermorelin

In vitro research has studied the working mechanism of Sermorelin. The research highlighted that the Sermorelin peptide has the potential to act like a growth hormone-releasing peptide (GHRP) in animals. The trials further elaborated that such acting, like GHRP, has influenced the patterns associated with the release of growth hormones. 

Key Similarities Between Hexarelin and Sermorelin Peptide

The following are some of the key similarities between hexarelin and sermorelin peptides found during clinical trials: 

Synthetic peptides

Both hexarelin and sermorelin are synthetic peptides. This means they are formed in the laboratory to explore their beneficial nature in research studies. 

Influence on Growth Hormone

Hexarelin and sermorelin peptides have a similar effect on growth hormones in research subjects in the trials. They have also been observed to have similar potential to affect the biomarkers associated with growth hormone secretion in subjects. 

Similar Potential Benefits

They have been studied to have similar benefits in research models during the trials. For instance, they may influence the patterns linked with myofibrillar protein synthesis, lipolytic activity, skeletal tissue integrity, and appetite-related neuroendocrine regulation in experimental models.

Purpose

The purpose of their use is the same. They are both used to explore their nature in relation to growth hormones. This means that they have been studied to observe their influence on the release of growth hormones in research subjects during research trials. 

Research Use

They are only used for research and exploration purposes; they are not allowed for human consumption. 

Key Differences Between Hexarelin and Sermorelin

Although both Hexarelin and Sermorelin peptides are similar in mimicking the effects of GHRP in research subjects, they also possess specific differences. Here are the key differences between Hexarelin and Sermorelin peptides: 

Mechanism of Action

Research studies have found that hexarelin may bind with ghrelin receptors and thus influence the patterns associated with the secretion of growth hormones. On the other hand, sermorelin may mimic the effect of growth hormone-releasing peptides and influence the pituitary gland in research models during the trials. Such influence may affect the biomarkers linked with the release of growth hormones in subjects. 

Side Effects and Safety

In preclinical trials, hexarelin peptide has been studied to have a higher tendency to cause mild side effects in research subjects. It also needs guidance from an experienced researcher to prevent its side effects. In contrast, sermorelin peptide has been shown to cause minimal side effects in research studies. Further, it has fewer safety concerns in research investigations than hexarelin.  

Intensity

Hexarelin was found to have a higher intensity in affecting the patterns related to GH secretion in the subjects studied. On the other hand, the sermorelin peptide may affect the patterns linked with GH release with a moderate tendency in research trials. 

Side Effects

Though Hexarelin and Sermorelin peptides have shown promising benefits in research studies, they may cause mild to moderate side effects. These side effects are as follows: 

• Articular sensitivity
• Peripheral paresthesia
• Hyperphagic response
• Cephalic discomfort
• Gastrointestinal disturbance
• Localized dermal reaction at administration site
• Affective variability

Note: Reported side effects in preclinical studies were generally mild and manageable under controlled laboratory conditions. However, further investigation is required to fully understand their safety profiles.

Legality Status

When legal status is considered, neither the FDA nor WADA approves it because very few trials have yet been conducted on both compounds. Therefore, they are not allowed to be sold for human consumption. However, researchers and scientists can buy it only for laboratory and research purposes. 

Which Option is Better?

Many researchers are still confused about deciding between Hexarelin and Sermorelin peptides for their research exploration. We have made this task easy for you.

After carefully analyzing previous research studies in animal models, Sermorelin may represent a favorable candidate. It has demonstrated potential in modulating growth hormone secretion profiles associated with myogenic pathways and biomarkers of cellular aging in experimental settings.

Moreover, sermorelin peptide may have a safe and naturally beneficial impact on research studies. 

Final Thought

Hexarelin and Sermorelin are the two synthetic peptides under clinical trials. They have been studied to determine their potential against growth hormones in research subjects in the trials.

This potential may influence physiological patterns related to myofibrillar development, lipid metabolism, energy intake regulation, and skeletal tissue integrity in research models during experimental trials. In addition to these observed effects, mild to moderate responses such as gastrointestinal disturbance, cephalic discomfort, and localized dermal reactions at the administration site have also been reported in research subjects.

Despite potential benefits, they have not yet been approved for human consumption and are still under clinical trials. 

Frequently Asked Questions (FAQS)

Is Hexarelin better than Ipamorelin?

Both have been studied for their potential to influence growth hormone release in research models during clinical trials. Hexarelin is observed to have a strong and fast tendency to release growth hormone in research subjects in trials. On the other hand, Ipamorelin has also been found in trials to have a higher tendency to secrete growth hormone with minimal side effects. 

Does Hexarelin increase cortisol in research subjects?

Yes, preclinical studies on animals have shown a slight increase in cortisol levels. 

What is the best place to buy Hexarelin and Sermorelin peptides online?

The best place to buy hexarelin and sermorelin peptides online is BehemothLabz. We not only sell products but also provide detailed information. We also assist researchers or scientists with product purchasing and post-research queries via efficient customer support 24/7. 

Is sermorelin a steroid?

No, sermorelin is not a steroid. It is a synthetic peptide (a long chain of amino acid molecules) and an analog of growth hormone-releasing peptide. 

What does Sermorelin do to research subjects in clinical research?

Sermorelin has the potential to influence the patterns related to releasing Growth Hormone (GH), improving its levels in research subjects. Such increased GH levels may modulate physiological and molecular markers associated with muscle tissue development, lipid metabolism, age-related cellular processes, and metabolic function in research models.

References

1. Ghigo, Ezio, et al. “Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.” The Journal of Clinical Endocrinology & Metabolism 78.3 (1994): 693-698.
2. Sibilia, V., et al. “Hexarelin, a growth hormone–releasing peptide, counteracts bone loss in gonadectomized male rats.” Growth Hormone & IGF Research 9.4 (1999): 219-227.
3. Prakash, Amitabh, and Karen L. Goa. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs 12 (1999): 139-157.
4. Walker, Richard F. “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?.” Clinical interventions in aging 1.4 (2006): 307-308.